Meta Platforms (NASDAQ:META | META Price Prediction) stock just earned a strong endorsement from UBS, which raised its price target on shares from $872 to $908 while maintaining a Buy rating. The firm’s bull thesis centers on continued GenAI-driven ad revenue growth and expected upward EPS and valuation revisions through 2026. For long-term investors, the revised target signals that at least one major Wall Street firm sees the GenAI ad machine as still early in its run.
Wall Street isn’t unanimous on META stock, however. Yesterday’s more cautious take from BofA trimmed its Meta Platforms stock price target to $820 while staying bullish, citing near-term ad-spend concerns. UBS is taking the opposite stance, leaning into the offensive case that GenAI tailwinds are accelerating, not plateauing.
| Ticker | Company | Firm | Action | Old Rating | New Rating | Old Target | New Target |
|---|---|---|---|---|---|---|---|
| META | Meta Platforms | UBS | Price Target Raised | Buy | Buy | $872 | $908 |
The Analyst’s Case
UBS points to GenAI-driven ad revenue growth as the primary engine behind the revised target, with additional upside from potential updates on AI chatbot and other monetization initiatives following Muse’s release. The firm expects upward EPS and valuation revisions to continue through 2026 as these initiatives mature. That’s a forward-looking bet on execution, not just current results.
The underlying ad data supports this thesis. In Q4 2025, Meta Platforms’ ad impressions rose 18% year over year while average price per ad climbed 6%. CFO Susan Li noted on the earnings call that “a new runtime model across Instagram feed stories and reels resulted in a 3% increase in conversion rates in Q4,” with model consolidation driving a 12% increase in ad quality. They’re compounding advantages that build on each other quarter after quarter.
Company Snapshot
Meta Platforms operates Facebook, Instagram, Messenger, WhatsApp, Threads, and Meta Quest. The company generated full-year 2025 revenue of $200.97 billion, up 22% year over year, with operating cash flow of $115.8 billion. Family daily active people reached 3.58 billion in Q4, a user base that makes Meta Platforms’ ad targeting scale essentially unmatched.
Why the Move Matters Now
Meta Platforms shares are trading around $674 as of this morning, well below the new $908 UBS target. The broader analyst consensus sits at $855.76, with 61 Buy or Strong Buy ratings and zero Sells among covering analysts. UBS’s target is the more aggressive call in that pack. The company’s forward P/E ratio stands at roughly 23x, which looks reasonable if the GenAI ad thesis delivers the EPS revisions UBS anticipates. The prediction markets assign a 92% probability to Meta Platforms beating Q1 2026 earnings, due April 29, which could serve as the next near-term catalyst.
What It Means for Your Portfolio
If you’re a long-term, income-focused investor, the UBS raise is worth taking seriously, but context matters. Meta Platforms is committing $115 to $135 billion in capital expenditures in 2026 to build out AI infrastructure, a massive bet that free cash flow will follow. Reality Labs posted a $19.2 billion operating loss in full-year 2025, and EU regulatory headwinds remain real. The split between UBS’s $908 and BofA’s $820 tells you something important: the range of reasonable outcomes here is genuinely wide. Watch for whether Q1 2026 earnings, reporting April 29, show continued ad impression and pricing momentum. That’s the data that will determine which analyst’s call ages better.
Position sizing matters here. Given the wide analyst target range and the scale of Meta Platforms’ 2026 capital commitments, investors should weigh their conviction against the execution risk that comes with era-defining infrastructure bets. A phased approach — holding a core META stock position while watching Q1 2026 results for confirmation — may be more prudent than going all-in ahead of the print.
Top Gaining Stocks
Top Losing Stocks